Article

Nusinersen in Infants Who Initiate Treatment in a Presymptomatic Stage of Spinal Muscular Atrophy (SMA): Interim Efficacy and Safety Results From the Phase 2 NURTURE Study (S25.001)

2019-04-09

Abstract excerpt

To present interim results from the ongoing NURTURE study (NCT02386553) examining efficacy/safety of intrathecal nusinersen, initiated prior to symptom onset, in infants most likely to develop SMA Type I/II.

Topics

Open a Topic to create a Post that cites this publication.

Neurogenetic and Muscular Disorders Research

Identifiers and source

Literature Corpus work: 8e5cd41b-06e2-51a5-ae9a-3c32b56dc240
DOI: 10.1212/wnl.92.15_supplement.s25.001

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Nusinersen in Infants Who Initiate Treatment in a Presymptomatic Stage of Spinal Muscular Atrophy (SMA): Interim Efficacy and Safety Results From the Phase 2 NURTURE Study (S25.001)DOI 10.1212/wnl.92.15_supplement.s25.001Read

Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE studySemantic proximity Read

Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.Semantic proximity Read

Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence.Semantic proximity Read

The Effects of Nusinersen Treatment on Respiratuar Status of Children with Spinal Muscular AtrophySemantic proximity Read

The respiratory impact of novel therapies for spinal muscular atrophy.Semantic proximity Read

Respiratory effects of nusinersen treatment in pediatric patients with spinal muscular atrophy types 2 and 3Semantic proximity Read

The Antisense Oligonucleotide Nusinersen for Treatment of Spinal Muscular AtrophySemantic proximity Read

Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular AtrophySemantic proximity Read

New treatments in spinal muscular atrophy.Semantic proximity Read

High Expression of SMN circ4-2b-3 in SMA I Children Treated with Nusinersen is Associated with Improved Motor OutcomesSemantic proximity Read

Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patientsSemantic proximity Read

Nusinersen as a Therapeutic Agent for Spinal Muscular AtrophySemantic proximity Read